Supernus Pharmaceuticals
SUPN
225 hedge funds and large institutions have $1.58B invested in Supernus Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 83 increasing their positions, 83 reducing their positions, and 26 closing their positions.
1.31% more ownership
Funds ownership: 101.19% → 102.49% (+1.3%)
4% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 26
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 83
2% less funds holding
Funds holding: 229 → 225 (-4)
9% less capital invested
Capital invested by funds: $1.75B → $1.58B (-$163M)
35% less call options, than puts
Call options by funds: $1.54M | Put options by funds: $2.36M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$46.2M |
| 2 |
Millennium Management
New York
|
+$6.99M |
| 3 |
Morgan Stanley
New York
|
+$6.91M |
| 4 |
LCG
Lisanti Capital Growth
New York
|
+$5.45M |
| 5 |
JP Morgan Chase
New York
|
+$5.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$8.27M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
-$7.86M |
| 3 |
Goldman Sachs
New York
|
-$6.95M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$5.19M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.7M |
SUPN Hedge Fund Activity: Q2 2022 in Review
225 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q2 2022, worth a combined $1.58B — down 9.3% from $1.75B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new SUPN positions and 26 closed out — a net gain of 1 holder — while 83 added to existing stakes and 83 trimmed.
The largest buyer was Armistice Capital, adding an estimated $46.2M. The largest seller was International Biotechnology Trust, cutting an estimated $8.27M.
- 225 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q2 2022, down from 229 in Q1 2022.
- Funds reported $1.58B of Supernus Pharmaceuticals stock for Q2 2022, down 9.3% quarter-over-quarter.
- 27 funds opened new Supernus Pharmaceuticals positions in Q2 2022 and 26 closed out, a net change of +1 holder.
- The largest Supernus Pharmaceuticals buyer in Q2 2022 was Armistice Capital, an estimated $46.2M added.
- The largest Supernus Pharmaceuticals seller in Q2 2022 was International Biotechnology Trust, an estimated $8.27M sold.
Based on aggregated 13F filings for Q2 2022.